Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
- Submitting institution
-
Institute of Cancer Research: Royal Cancer Hospital (The)
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 109
- Type
- D - Journal article
- DOI
-
10.1016/S0140-6736(15)01037-5
- Title of journal
- Lancet
- Article number
- -
- First page
- 1163
- Volume
- 387
- Issue
- 10024
- ISSN
- 1474-547X
- Open access status
- Out of scope for open access requirements
- Month of publication
- March
- Year of publication
- 2016
- URL
-
-
- Supplementary information
-
https://www.sciencedirect.com/science/article/pii/S0140673615010375?via%3Dihub#ecomp10
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
47
- Research group(s)
-
-
- Citation count
- 906
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- a) The author made a substantial contribution to the conception and design of the study; the organisation of the conduct of the study; carrying out the study; analysis and interpretation of study data.
b) The author helped draft the output
- Non-English
- No
- English abstract
- -